SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-16-000188
Filing Date
2016-10-24
Accepted
2016-10-24 06:03:22
Documents
5
Period of Report
2016-10-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-k102116.htm 8-K 47691
2 EXHIBIT 10.1 exhibit101101916.htm EX-10.1 5231
3 EXHIBIT 10.2 exhibit102102116.htm EX-10.2 158602
4 EXHIBIT 10.3 exhibit103102016.htm EX-10.3 11675
5 EXHIBIT 10.4 exhibit104102016.htm EX-10.4 85234
  Complete submission text file 0000891293-16-000188.txt   309885
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12465 | Film No.: 161947169
SIC: 2834 Pharmaceutical Preparations